EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Cost-effectiveness of sunitinib as second-line treatment for gastrointestinal stromal tumor in the People’s Republic of China

Jian Li, Hong Ye Ren, Juanjuan Zhang, Peng Dong, Yan Wang, Andrea Stevens, Yi Han, Min Huang

Comparative Effectiveness Research · 2017

DOI: 10.2147/cer.s110509 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Comparative Effectiveness Research, 2017. Verfasst von Jian Li und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Li, J., Ren, H. Y., Zhang, J., Dong, P., Wang, Y., Stevens, A., Han, Y., & Huang, M. (2017). Cost-effectiveness of sunitinib as second-line treatment for gastrointestinal stromal tumor in the People’s Republic of China. Comparative Effectiveness Research. https://doi.org/10.2147/cer.s110509

Vancouver

Li J, Ren HY, Zhang J, Dong P, Wang Y, Stevens A, et al. Cost-effectiveness of sunitinib as second-line treatment for gastrointestinal stromal tumor in the People’s Republic of China. Comparative Effectiveness Research. 2017. doi:10.2147/cer.s110509

BibTeX
@article{Li2017,
  author = {Li, Jian and Ren, Hong Ye and Zhang, Juanjuan and Dong, Peng and Wang, Yan and Stevens, Andrea and Han, Yi and Huang, Min},
  title = {Cost-effectiveness of sunitinib as second-line treatment for gastrointestinal stromal tumor in the People’s Republic of China},
  journal = {Comparative Effectiveness Research},
  year = {2017},
  doi = {10.2147/cer.s110509}
}
Kostenlos starten →